Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155090 | 1.00 | TAS2R14 (0.40) | TAS2R14TIPARPTSHRPRKCQPRKCD | |
| SCHEMBL28994459 | 0.82 | EPHX2 (0.37) | TIPARPPRKCQPRKCDARCTSS | |
| SCHEMBL28994460 | 0.82 | EPHX2 (0.37) | TIPARPPRKCQPRKCDARCTSS | |
| SCHEMBL30294671 | 0.79 | TAS2R14 (0.39) | TAS2R14TSHRLMNAIKBKETBK1 | |
| SCHEMBL22853016 | 0.79 | TAS2R14 (0.39) | TAS2R14TSHRLMNAIKBKETBK1 | |
| SCHEMBL22853012 | 0.79 | TAS2R14 (0.39) | TAS2R14TSHRLMNAIKBKETBK1 | |
| SCHEMBL30294557 | 0.79 | TAS2R14 (0.39) | TAS2R14TSHRLMNAIKBKETBK1 | |
| SCHEMBL22853404 | 0.76 | TAS2R14 (0.43) | TAS2R14PRKCQPRKCDAR | |
| SCHEMBL3630713 | 0.73 | PDE1B (0.41) | PRKCQPRKCDTBK1CTSKMEN1 | |
| SCHEMBL3630716 | 0.73 | PDE1B (0.41) | PRKCQPRKCDTBK1CTSKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | TAS2R14 1112/4885TIPARP 4441/4885TSHR 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.